

Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

<https://marketpublishers.com/r/GA7F4C71C61EN.html>

Date: May 2019

Pages: 126

Price: US\$ 5,650.00 (Single User License)

ID: GA7F4C71C61EN

Abstracts

The study involved four major activities in estimating the current size of the leukemia therapeutics market. Exhaustive secondary research was done to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research

Several stakeholders such as leukemia drug manufacturers, vendors, distributors and scientists, researchers, oncologist, and doctors from hospitals and clinics were

consulted for this report. The demand side of this market is characterized by the significant use of immunotherapies and targeted drugs for leukemia treatment owing to the increasing incidence rate of leukemia across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.

Note 2: Company tiers are defined by their total revenues. As of 2017, Tier 1: >USD 1 billion; Tier 2: USD 50 million to USD 1 billion; and Tier 3:

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 MARKETS COVERED
 - 1.2.2 YEARS CONSIDERED FOR THE STUDY
- 1.3 CURRENCY
- 1.4 LIMITATIONS
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 SECONDARY DATA
 - 2.2.1 KEY DATA FROM SECONDARY SOURCES
- 2.3 PRIMARY DATA
 - 2.3.1 KEY DATA FROM PRIMARY SOURCES
- 2.4 MARKET SIZE ESTIMATION
 - 2.4.1 BOTTOM-UP APPROACH
 - 2.4.2 TOP-DOWN APPROACH
- 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 LEUKEMIA THERAPEUTICS: MARKET OVERVIEW
- 4.2 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE & MODE OF ADMINISTRATION (2019)
- 4.3 GEOGRAPHICAL SNAPSHOT OF THE LEUKEMIA THERAPEUTICS MARKET

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS

- 5.2.1.1 Rising prevalence of leukemia
 - 5.2.1.1.1 Growth in geriatric population
 - 5.2.1.1.2 Rising cancer occurrence among children
- 5.2.1.2 Introduction of innovative therapies
- 5.2.2 RESTRAINTS
 - 5.2.2.1 Complexities in manufacturing
- 5.2.3 OPPORTUNITIES
 - 5.2.3.1 Growth opportunities in emerging economies

6 LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA

6.1 INTRODUCTION

6.2 CHRONIC MYELOID LEUKEMIA

6.2.1 CHRONIC MYELOID LEUKEMIA ACCOUNTS FOR THE LARGEST SHARE OF THE LEUKEMIA THERAPEUTICS MARKET PRIMARILY DUE TO THE HIGH INCIDENCE OF THIS DISEASE WORLDWIDE

6.3 CHRONIC LYMPHOCYTIC LEUKEMIA

6.3.1 THE INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA INCREASES WITH AGE AND IS MORE COMMON IN MEN THAN WOMEN

6.4 ACUTE LYMPHOCYTIC LEUKEMIA

6.4.1 ACUTE LYMPHOCYTIC LEUKEMIA MOSTLY AFFECTS CHILDREN BETWEEN

3 AND 7 YEARS OF AGE

6.5 ACUTE MYELOID LEUKEMIA

6.5.1 ACUTE MYELOID LEUKEMIA IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS

7 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE

7.1 INTRODUCTION

7.2 TARGETED DRUGS & IMMUNOTHERAPY

7.2.1 TARGETED DRUGS & IMMUNOTHERAPY SEGMENT ACCOUNTS FOR THE LARGER MARKET SHARE DUE TO THE HIGHER EFFICACY & SUCCESS RATE ASSOCIATED WITH THEM AS COMPARED TO CHEMOTHERAPY

7.3 CHEMOTHERAPY

7.3.1 CHEMOTHERAPY IS EFFECTIVE AND ESSENTIAL FOR CANCERS SUCH AS

LEUKEMIA THAT HAVE SPREAD THROUGHOUT THE BODY

8 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE

8.1 INTRODUCTION

8.2 SMALL MOLECULES

8.2.1 THE SMALL STRUCTURE AND CHEMICAL COMPOSITION OF SMALL MOLECULES HELP THEM TO EASILY PENETRATE CELL MEMBRANES

8.3 BIOLOGICS

8.3.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

9 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION

9.1 INTRODUCTION

9.2 ORAL MODE

9.2.1 DRUGS ADMINISTERED ORALLY HAVE LESSER COMPLICATIONS

9.3 INJECTABLE MODE

9.3.1 INJECTABLE MODE OF ADMINISTRATION IS LESS PREFERRED THAN THE ORAL MODE OF ADMINISTRATION

10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER

10.1 INTRODUCTION

10.2 MALES

10.2.1 MEN ARE AT HIGHER RISK OF DEVELOPING LEUKEMIA THAN WOMEN

10.3 FEMALES

10.3.1 ACUTE LYMPHOCYTIC LEUKEMIA REMAINS COMMON AMONG WOMEN

11 LEUKEMIA THERAPEUTICS MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 US

11.2.1.1 US accounted for the largest share of the North American market due to the high prevalence of leukemia in the country

11.2.2 CANADA

11.2.2.1 Government initiatives to support leukemia research and develop novel immunotherapies is expected to support the growth of the Canadian

leukemia therapeutics market

11.3 EUROPE

11.3.1 GERMANY

11.3.1.1 Germany has a strong foundation for R&D, including over

1,000 PUBLIC AND PRIVATE INSTITUTIONS

11.3.2 UK

11.3.2.1 Rising geriatric population in the country to drive market growth as the incidence of cancer is higher in the geriatric population

11.3.3 FRANCE

11.3.3.1 Rising R&D expenditure is a major growth driver in France

11.3.4 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 JAPAN

11.4.1.1 Comparatively lenient regulations and rising geriatric population will drive market growth

11.4.2 CHINA

11.4.2.1 Favorable investments and government support will contribute to the growth of the Chinese market

11.4.3 INDIA

11.4.3.1 Shortage of skilled professionals may restrain the growth of the Indian market

11.4.4 ROAPAC

11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 MARKET RANKING ANALYSIS, 2018

12.3 KEY STRATEGIES

12.3.1 REGULATORY APPROVALS/LAUNCHES

12.3.2 ACQUISITIONS

12.3.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

12.4 COMPETITIVE LEADERSHIP MAPPING (2018)

12.4.1 VENDOR INCLUSION CRITERIA

12.4.2 VISIONARY LEADERS

12.4.3 INNOVATORS

12.4.4 DYNAMIC DIFFERENTIATORS

- 12.4.5 EMERGING COMPANIES
- 12.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
 - 12.5.1 PROGRESSIVE COMPANIES
 - 12.5.2 STARTING BLOCKS
 - 12.5.3 RESPONSIVE COMPANIES
 - 12.5.4 DYNAMIC COMPANIES

13 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View)*

- 13.1 NOVARTIS AG
- 13.2 ABBVIE
- 13.3 BRISTOL-MYERS SQUIBB
- 13.4 F. HOFFMANN-LA ROCHE
- 13.5 SANOFI
- 13.6 PFIZER
- 13.7 AMGEN
- 13.8 GILEAD SCIENCES
- 13.9 TAKEDA
- 13.10 CELGENE

* Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View might not be captured in case of unlisted companies.

14 APPENDIX

- 14.1 INSIGHTS FROM INDUSTRY EXPERTS
- 14.2 DISCUSSION GUIDE
- 14.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.4 AVAILABLE CUSTOMIZATIONS
- 14.5 RELATED REPORTS
- 14.6 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 NUMBER OF NEW LEUKEMIA CASES, BY REGION

TABLE 2 ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS IN US

TABLE 3 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024
(USD MILLION)

TABLE 4 CHRONIC MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD
MILLION)

TABLE 5 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, BY REGION, 2017–2024
(USD MILLION)

TABLE 6 ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY REGION, 2017–2024
(USD MILLION)

TABLE 7 ACUTE MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD
MILLION)

TABLE 8 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024
(USD MILLION)

TABLE 9 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR LEUKEMIA,
BY REGION, 2017–2024 (USD MILLION)

TABLE 10 TARGETED DRUGS AND IMMUNOTHERAPY MARKET, BY LEUKEMIA
TYPE, 2017–2024 (USD MILLION)

TABLE 11 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE
LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 12 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC
LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 13 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC
MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 14 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE
MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 15 FEW EXAMPLES OF CHEMOTHERAPY DRUGS

TABLE 16 CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024
(USD MILLION)

TABLE 17 CHEMOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD
MILLION)

TABLE 18 CHEMOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY
REGION, 2017–2024 (USD MILLION)

TABLE 19 CHEMOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA,
BY REGION, 2017–2024 (USD MILLION)

TABLE 20 CHEMOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 21 CHEMOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)

TABLE 22 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017–2024 (USD MILLION)

TABLE 23 FEW IMPORTANT SMALL MOLECULES USED TO TREAT DIFFERENT LEUKEMIA TYPE

TABLE 24 LEUKEMIA THERAPEUTICS MARKET FOR SMALL MOLECULES, BY REGION, 2017–2024 (USD MILLION)

TABLE 25 FEW IMPORTANT BIOLOGICS FOR THE TREATMENT OF DIFFERENT LEUKEMIA TYPE

TABLE 26 LEUKEMIA THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION, 2017–2024 (USD MILLION)

TABLE 27 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION, 2017–2024 (USD MILLION)

TABLE 28 LEUKEMIA THERAPEUTICS MARKET FOR ORAL MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)

TABLE 29 LEUKEMIA THERAPEUTICS MARKET FOR INJECTABLE MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)

TABLE 30 LEUKEMIA AT A GLANCE (US)

TABLE 31 GLOBAL LEUKEMIA CASES (2018), BY COUNTRY AND GENDER & FORECAST (2020)

TABLE 32 LEUKEMIA INCIDENCE AND DEATHS, BY GENDER (2018)

TABLE 33 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 34 LEUKEMIA THERAPEUTICS MARKET FOR MALES, BY REGION, 2017–2024 (USD MILLION)

TABLE 35 LEUKEMIA THERAPEUTICS MARKET FOR FEMALES, BY REGION, 2017–2024 (USD MILLION)

TABLE 36 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)

TABLE 37 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)

TABLE 38 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 39 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 40 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,

2017–2024 (USD MILLION)

TABLE 41 US: LEUKEMIA AT A GLANCE

TABLE 42 US: LEUKEMIA, BY TYPE (2017 VS. 2018)

TABLE 43 US: LEUKEMIA NEW CASES & DEATHS, BY STATE (2019)

TABLE 44 US: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 45 US: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 46 US: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 47 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 48 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 49 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 50 RESEARCH FUNDING: EUROPEAN OVERVIEW

TABLE 51 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)

TABLE 52 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 53 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 54 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 55 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 56 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 57 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 58 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATE PER 100,000 POPULATION (ACUTE LYMPHOCYTIC LEUKEMIA)

TABLE 59 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC LYMPHOCYTIC LEUKEMIA)

TABLE 60 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (ACUTE MYELOID LEUKEMIA)

TABLE 61 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS)

INCIDENCE RATES PER 100,000 POPULATION (CHRONIC MYELOID LEUKEMIA)

TABLE 62 UK: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 63 UK: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 64 UK: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 65 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 66 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 67 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 68 ROE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 69 ROE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 70 ROE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 71 APAC: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)

TABLE 72 APAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 73 APAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 74 APAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 75 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 76 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 77 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 78 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 79 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 80 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 81 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 82 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 83 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 84 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 85 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 86 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 87 ROW: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)

TABLE 88 ROW: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)

TABLE 89 ROW: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)

TABLE 90 LEUKEMIA THERAPEUTICS MARKET RANKING BY KEY PLAYER, 2018

List Of Figures

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 3 LEUKEMIA THERAPEUTICS MARKET: BOTTOM-UP APPROACH

FIGURE 4 LEUKEMIA THERAPEUTICS MARKET: TOP-DOWN APPROACH

FIGURE 5 DATA TRIANGULATION METHODOLOGY

FIGURE 6 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2019 VS. 2024 (USD MILLION)

FIGURE 7 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE, 2019 VS. 2024 (USD MILLION)

FIGURE 8 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION, 2019 VS. 2024 (USD MILLION)

FIGURE 9 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE, 2019 VS. 2024 (USD MILLION)

FIGURE 10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2019 VS. 2024 (USD MILLION)

FIGURE 11 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD MILLION)

FIGURE 12 HIGH PREVALENCE RATE OF LEUKEMIA TO DRIVE MARKET GROWTH

FIGURE 13 ORAL AND TARGETED DRUGS & IMMUNOTHERAPY SEGMENTS TO DOMINATE THE MARKET IN 2019

FIGURE 14 US TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

FIGURE 15 LEUKEMIA THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES

FIGURE 16 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET SNAPSHOT

FIGURE 17 KEY DEVELOPMENTS IN THE LEUKEMIA THERAPEUTICS MARKET (2016-2018)

FIGURE 18 MNM DIVE-VENDOR COMPARISON MATRIX: LEUKEMIA THERAPEUTICS MARKET

FIGURE 19 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: LEUKEMIA THERAPEUTICS MARKET

FIGURE 20 NOVARTIS: COMPANY SNAPSHOT (2018)

FIGURE 21 ABBVIE INC.: COMPANY SNAPSHOT (2018)

FIGURE 22 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2018)

FIGURE 23 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2018)

FIGURE 24 SANOFI: COMPANY SNAPSHOT (2018)

FIGURE 25 PFIZER: COMPANY SNAPSHOT (2018)

FIGURE 26 AMGEN: COMPANY SNAPSHOT (2018)

FIGURE 27 GILEAD SCIENCES: COMPANY SNAPSHOT (2018)

FIGURE 28 TAKEDA: COMPANY SNAPSHOT (2018)

FIGURE 29 CELGENE: COMPANY SNAPSHOT (2018)

I would like to order

Product name: Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

Product link: <https://marketpublishers.com/r/GA7F4C71C61EN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA7F4C71C61EN.html>